Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL

Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, shares some results from a Phase I study evaluating the safety and efficacy of a novel synthetic TCR and antigen receptor (STAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL). Dr Lu first explains the rationale behind the development of this agent, which aims to increase the efficacy and decrease the side effects associated with CAR-T therapy. Dr Lu then discusses the results from this study and concludes by highlighting potential future applications of this agent in other hematological malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.